TOWARDS A NOVEL COMBINATION THERAPY AGAINST HUMAN TUMORS BASED ON THE SYNERGISTIC ANTI-CANCER EFFECT OF TWO NON-CANCER DRUGS

• Unité de recherche: INNOSUISSE
• Numéro de projet: 12638.1;12 PFLS-LS
• Titre du projet anglais: TOWARDS A NOVEL COMBINATION THERAPY AGAINST HUMAN TUMORS BASED ON THE SYNERGISTIC ANTI-CANCER EFFECT OF TWO NON-CANCER DRUGS

Description succincte (Allemand)

TOWARDS A NOVEL COMBINATION THERAPY AGAINST HUMAN TUMORS BASED ON THE SYNERGISTIC ANTI-CANCER EFFECT OF TWO NON-CANCER DRUGS

Description succincte (Anglais)

TOWARDS A NOVEL COMBINATION THERAPY AGAINST HUMAN TUMORS BASED ON THE SYNERGISTIC ANTI-CANCER EFFECT OF TWO NON-CANCER DRUGS

Résumé des résultats (Abstract) (Allemand)

It was recently discovered at the University of Basel that combining a well known metabolic drug with a drug not previously reported to have any potential for the treatment of cancer led to an unexpected and synergistic anti-tumor effect. We aim to pursue this novel anti-cancer approach to the clinic. Proposed are chemical modifications to optimize one of the combination partners, as well as toxicological and pharmacological studies. In parallel, mechanistic studies, including identification of drug binding/effector genes, will be performed in order to define biomarkers of drug response and guide drug development.

Résumé des résultats (Abstract) (Anglais)

It was recently discovered at the University of Basel that combining a well known metabolic drug with a drug not previously reported to have any potential for the treatment of cancer led to an unexpected and synergistic anti-tumor effect. We aim to pursue this novel anti-cancer approach to the clinic. Proposed are chemical modifications to optimize one of the combination partners, as well as toxicological and pharmacological studies. In parallel, mechanistic studies, including identification of drug binding/effector genes, will be performed in order to define biomarkers of drug response and guide drug development.